Scopus BioPharma Inc.

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Pfizer Licenses Spero’s I.V. Anti-Infec

The stars aligned in 2020 for a record-breaking year of 86 biopharmaceutical companies launching initial public offerings in the US, which raised $17.04bn and generated an 86% average return as of 27

Inhibikase Therapeutics, Inc. launched the last initial public offering of 2020 by a biopharmaceutical company, bringing the year’s total to 86 IPOs in the US. First-time offerings already are off to

BioAtla, Inc. , Virios Therapeutics, Inc. and Scopus BioPharma Inc. brought the number of initial public offerings by biopharmaceutical companies in the US to 85 so far in 2020 as investors prepar